Indore

National Seminar on "Recent Innovations and Developments in Pharmaceutical Sciences and Technology" April, 27th, 2014 in Rishiraj College of Pharmacy

LNCT Group of Colleges is ones of the oldest and largest education group in central India. Founded in 1994, LNCT Group of Colleges has the privilege of being the First Private (self financed ) institute of M.P LNCT Group offers Diploma, Bachelor, Master's and Doctorate-level programs in Engineering, Management, Pharmacy, Medical, Homeopathy, Dental and recurring and professional studies.


Panacea Biotec recruiting Executive - Sales and Market Development

Panacea Biotec is a leading research based Health Management Company, with an annual turnover of approx. Rs. 830 Crores. We are engaged in research, development, manufacture & marketing of Vaccines, Bio-Pharmaceuticals and Pharmaceuticals (Rx & OTC) of international quality and Health Services. All Panacea Biotec plants are accredited by international agencies and they follow current Good Manufacturing Practices, as per WHO guidelines.
We offer stimulating work environment & a career that spells growth. In tune with our plans, we require young, aggressive, dynamic, high performing and result oriented professional.

Post: Executive Sales and Market Development


NEXT LIPITOR® WILL ALSO BE FROM METABOLIC THERAPY

Introduction
At least one article is seen in newspaper on obesity on daily basis; no other disease is searched (and articles are read on) as frequently as obesity. Such is the menace of obesity that even fast food giant McDonald's has put an advice in few of its offices “not to eat too much fast-food”. Obesity is defined as BMI (body mass index) 30kg\m2 or more. A person with a BMI between 25 and 29.9 are considered over weight but not obese. BMI is a simple index of weight-for-height that is commonly used to classify overweight and obesity in humans. It is also defined as a person’s weight in kilograms divided by the square of his height in meters (kg\m2). As per world health organization (WHO), BMI greater than or equal to 25 is overweight and BMI greater than or equal to 30 is obese. Obesity is a foremost health problem not only in developed nations but also in developing countries. It increases the risk of other diseases like diabetes, cardiovascular ailments, fatty liver and some forms of cancer1. Obesity is now so common in various geographies that it is beginning to replace conditions arising from malnutrition and infectious diseases as the most significant contributor to ill health. Obesity is measured using BMI and further evaluated in terms of fat distribution via the waist–hip ratio and total cardiovascular risk factors2. BMI is closely related to both percentage body fat and total body fat3. The global epidemic of obesity results from an amalgamation of such factors as genetic susceptibility, increased availability of high-energy foods and diminished need of physical activity in prevailing situation in modern society. Obesity is no more a cosmetic issue affecting certain individuals, but a pandemic threatening global well being because it exacerbates a large number of health-related problems, both independently and in association with other ailments4,5.


GENERIC DAVIDS AND INNOVATOR GOLIATHS

{ DOWNLOAD AS PDF }

ABOUT AUTHOR:
Amit Gangwal
Department of Pharmacognosy,
Smriti college of pharmaceutical education, Indore, Madhya Pradesh, India
gangwal.amit@gmail.com

ABSTRACT
Patents provide an incentive to the pharmaceutical industry to invest in the development of new medicines to treat diseases that are currently untreatable or incurable, and provide options when patients develop resistance to older drugs. Around the world it has been a challenge for last one or two decades to innovate concepts and mechanisms to hasten the drug development schemes/process, while augmenting dereplication ways in a full proof manner to save time, man power and financial input. High failure rate at any stage in drug development process is bothering and evoking various tools to be discussed like never before. The pharmaceutical industries world over, are in a period of crisis due to the poor number of approved drug molecules relative to the high levels of R&D investment. The drug industry is facing major scientific and strategic challenges. Moreover competition from generic giants is giving tough challenge to established products owing to end of patent rights. The concerns are further aggravated by couple of decisions announced by Indian courts (Nexavar® followed by long time pending battle of Gleevac®). These two decrees by Indian courts were not ruled in the favor of pharma giants; Bayer and Novartis respectively. Millions are dying in various part of world, owing to their inability to purchase the Elite Drugs, because of intellectual property rights. In this article various pros and cons have been discussed pertaining to generic medicines and patent fights of innovators world over.


Vacancies for STATE HEAD (DEPUTY MANAGER / ASSISTANT MANAGER) in HLL Lifecare - 8 posts

HLL Lifecare Limited, a Mini Ratna Central Public Sector Enterprise under the Ministry of Health & Family Welfare, Govt. of India is a global provider of high quality healthcare products & services. With state-of-the-art manufacturing facilities spanning across India, HLL is diversifying into vaccine manufacturing, lifecare services, sanitary napkins besides engaging in procurement consultancy, healthcare infrastructure development and facility management.

Post: STATE HEAD (DEPUTY MANAGER / ASSISTANT MANAGER)


PRODRUGS: AN OVERVIEW

About Authors:
Deepti Soni*, Rathore KS1, Nema RK2
*College of Pharmaceutical Sciences, Behrampur, Orissa
1BN Institute of Pharmaceutical Sciences, Udaipur, Raj.
2Rishiraj College of Pharmacy, Indore-MP
*deepti_jazz@yahoo.com

Introduction
A prodrug is a pharmacological substance (drug) that is administered in an inactive (or significantly less active) form. Once administered, the prodrug is metabolised in vivo into an active metabolite (Wadhwa LK, 1994). Almost all drugs possess some undesirable physiochemical and biological properties. Their therapeutic efficacy can be improved by minimizing or eliminating the undesirable properties while retaining the desirable ones.  This can be achieved through biological, physical or chemical means (Loe A, 1971, Balant LP, E Doelker, et al., 1990, Jha V, 1995).

  • The biological approach is to alter the route of administration, which may or may not be acceptable to the patient.
  • The physical approach is to modify the design of the dosage form such as controlled delivery of drugs.
  • The chemical approach is the best approach in enhancing drug selectivity and minimizing the toxicity.


Walk in interview for the post of QC, Production (api) & Pilot Plant in IPCA Laboratories | 35 Posts

Ipca now plus Rs.2700 Crores Company is global player with significant presence in over 110 countries with high brand equity in the domestic and international markets
Our manufacturing facilities of bulk drugs at Ratlam have earned accreditations and approvals from the worlds most vigilant regulatory bodies.


Pages